Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of JNJ-70075200 in Healthy Participants
NCT04782661Phase 1Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2022
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JNJ-70075200 (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Percentage of Participants with Treatment Emergent Adverse Events, Percentage of Participants with Serious Adverse Events and 8 more. Planned start Mar 2022; status: withdrawn.
02
Drugs
JNJ-70075200
Beyond the preview
Go deeper on NCT04782661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04782661.